Selank: research overview

The short version

Selank is a synthetic peptide seven amino acids long, built from the immune peptide tuftsin with a Pro-Gly-Pro tail grafted on to slow its breakdown. In animal models it reduces anxiety through a mechanism quite different from benzodiazepines: it appears to act as a positive allosteric modulator of GABA receptors — nudging their sensitivity without sitting in the same binding pocket as diazepam — and also stabilizes the brain's own opioid peptides (enkephalins) by inhibiting the enzymes that degrade them ^[8][7]. In rat models, it also upregulates BDNF in the hippocampus ^[11]. Human work is limited, mostly Russian, and confined to short-course trials in patients with anxiety-related disorders ^[12].

Here is the honest part. Selank is not approved by the FDA or EMA for any indication. It is registered as a prescription anxiolytic only in Russia, and only there does it have a formal clinical history. Everywhere else it is an unscheduled research chemical. This page summarizes what the published literature says; it is not medical advice and never cites a dose. Selank and Semax are strictly different compounds — different sequences, different primary mechanisms, and no meaningful pharmacological overlap — and this desk covers them separately.

What it is

Selank (also called TP-7 in the Russian research literature; full sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide derived from tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) that is a fragment of the IgG heavy chain and is involved in innate immune regulation. Extending tuftsin by adding Pro-Gly-Pro at the C-terminus slows enzymatic degradation and increases metabolic stability, which is the structural rationale for the modification.

Selank and Semax are sometimes grouped together because both are Russian-origin heptapeptides ending in Pro-Gly-Pro, but they are otherwise entirely distinct. Selank's first four amino acids derive from tuftsin (an immune peptide), while Semax's derive from ACTH(4-7) (a hormone fragment). Their primary studied endpoints are different — Selank's research centers on anxiolytic activity, Semax's on neurotrophin upregulation and neuroprotection — and the subjective profiles that research communities report for each are qualitatively different.

In Russia, Selank is registered as a prescription drug indicated for anxiety and asthenic disorders. In the United States and EU, it has no approved indication and is classified as a research chemical.

How it works

Selank's best-characterized mechanism is positive allosteric modulation of GABA receptor binding. A 2018 molecular review established that Selank modulates [³H]GABA binding to rat brain membranes in a subtype-selective, concentration-dependent manner that differs from benzodiazepines — it can actually block diazepam's and olanzapine's modulatory effects on the receptor, indicating distinct but overlapping binding sites ^[8]. In an unpredictable chronic mild stress model in rats, the combination of diazepam plus Selank produced the largest anxiety reduction of any single or combined treatment, consistent with a GABAergic interaction ^[9].

A second mechanism is inhibition of enkephalin-degrading enzymes. In human serum in vitro, Selank inhibited the same neprilysin-type peptidases that break down enkephalins (IC50 ~20 micromolar), stabilizing the brain's endogenous opioid peptides — an effect shared with Semax, though at a weaker potency in that study ^[7]. Gene-expression work in rat frontal cortex found that Selank changed the expression of 45 GABA-pathway genes at one hour after administration and 22 at three hours, with changes positively correlated with those produced by GABA itself ^[10].

Selank also increases hippocampal BDNF expression in rats after intranasal administration ^[11], linking it to the same neurotrophin axis that characterizes Semax — though this is a secondary finding in Selank's research history rather than a primary characterization. Its tuftsin lineage gives it a fourth axis: immune modulation, specifically a shift in Th1/Th2 cytokine balance and modulation of IL-6 in patients with anxiety-asthenic disorders ^[12].

What the research shows

GABA allosteric modulation. Vyunova et al. (2018) characterized Selank's GABA-receptor interaction in detail, establishing it as a positive allosteric modulator with concentration-dependent, subtype-selective action distinct from classical benzodiazepines ^[8]. The distinction from benzodiazepines is not just pharmacological — it is the mechanistic reason researchers describe Selank as a potential "non-benzodiazepine anxiolytic."

Enhanced anxiolytic effect with GABAergic agents. Kasian et al. (2017) found that combining diazepam with Selank in a chronic mild-stress rat model produced the strongest reduction in anxiety-related behavior of any single or combined treatment tested, restoring behavior toward pre-stress baselines ^[9]. This supports a GABAergic mode of action and raises a practical caution: it also means the combination amplifies sedative effects.

GABA-pathway gene expression. Volkova et al. (2016) measured gene expression in rat frontal cortex after Selank and found significant shifts in 45 GABA-pathway genes at one hour and 22 at three hours, with a positive correlation between Selank-induced and GABA-induced expression changes — consistent with, and providing a transcriptional basis for, the receptor-modulation findings ^[10].

Hippocampal BDNF upregulation. Inozemtseva et al. (2008) found that intranasal Selank in Wistar rats raised BDNF expression in the hippocampus in vivo ^[11] — neuroplasticity-relevant and mechanistically interesting, though studied less intensively than the same endpoint in Semax research.

Human immunomodulatory evidence. Uchakina et al. (2008) studied Selank in patients with anxiety-asthenic disorders and found it altered the Th1/Th2 cytokine balance and modulated IL-6 expression in peripheral blood, characterizing it as an immunomodulator as well as an anxiolytic ^[12]. This is one of the only human datasets on Selank in mainstream literature; it is Russian, single-center, and in a specific clinical population.

What the evidence does not show. Selank has not been studied in Western randomized controlled trials. Evidence for treating diagnosable anxiety disorders should not be extrapolated from the existing dataset. Formal pharmacokinetic characterization in humans is sparse.

Reported effects, cautions & safety

The following account of real-world community reports is drawn from nootropic forums, biohacker writeups, and peptide-user communities. These are anecdotal reports, not clinical evidence. They are subjective impressions, not controlled outcomes.

What people commonly report as benefits:

• Calm without sedation. The most consistent description across positive accounts is a softening of background anxiety that does not feel like being drugged or slowed down. People describe it as the volume on anxious thoughts being turned down while energy and clarity hold steady — frequently contrasted explicitly with the heavy fog of benzodiazepines or emotional flatness of SSRIs.
• Reduced situational and social anxiety. Users very often take it situationally — before a presentation, exam, or difficult conversation — and report markedly fewer nerves, with social interaction feeling less effortful and draining. These are subjective community reports; they do not constitute evidence that Selank treats any anxiety disorder.
• Fast onset via the intranasal route. People commonly report noticing a shift within roughly 20 to 40 minutes of an intranasal dose, which drives its use as an as-needed situational tool. Reported timing varies and is anecdotal.
• Calm but sharp focus. A recurring theme is a "calm but sharp" state: easier concentration once anxious mental chatter quiets down. Most attribute this to the anxiety relief itself rather than a direct stimulant-like push — a quieter route to focus than Semax.
• Mood stabilization over days to weeks. Many describe a gradual leveling of mood and stress reactivity over one to two weeks of regular use, described as cumulative and separate from the immediate per-dose calm.

What a meaningful portion of users reports as negatives or mixed:

• Short single-dose duration. Very commonly reported: the noticeable per-dose effect lasts only a few hours, consistent with short peptide half-life.
• Subtle or no effect for some people. A recurring counterpoint: some users finish an entire vial and feel nothing, or find the effect too gentle to be useful. Non-response is a real and commonly voiced part of the picture.
• Mild over-calm or drowsiness in a minority. Some report feeling slightly too calm, mentally soft, or briefly low-energy — especially when using frequently or at higher amounts. Usually described as mild and reversible.
• Nasal irritation. Dryness, burning, stinging, or brief sneezing is among the most commonly mentioned downsides with intranasal use. Generally attributed to the carrier solution and spray technique rather than the peptide itself.
• No dependence or rebound reported, with an important caveat. Unlike benzodiazepines, users do not commonly describe tolerance escalation or a withdrawal syndrome — but this observation rests on short-term anecdotal experience, not long human safety trials. Psychological reliance on anything that reliably reduces anxiety is still possible.

Key safety cautions from the literature:

• Unregulated research-chemical supply. Outside Russia, Selank carries no pharmaceutical-grade quality controls; identity, purity, and actual peptide content vary by supplier ^[8].
• Long-term human safety not established. Human data are largely confined to a small set of Russian clinical studies of a few weeks' duration. Short, single-region trials cannot characterize chronic or repeated long-term use ^[8][9].
• Multi-system interaction unknowns. Selank touches GABAergic, opioid-enkephalin, monoaminergic, and immune-cytokine systems. Combining it with GABAergic sedatives, opioids, serotonergic drugs, or immune-modulating medications faces essentially unstudied interaction potential ^{[8][9][10][7][12]}.
• Immune-signaling axis. As a tuftsin analog, Selank modulates Th1/Th2 cytokine balance. The downstream consequences of repeatedly shifting immune signaling are not characterized in long-term human use, and this is a mechanism-based reason for caution in people with autoimmune conditions or on immune-modulating medications ^[12].
• Not a substitute for clinical care. Persistent or impairing anxiety is a medical condition with established evidence-based treatments. An unapproved research peptide is not a substitute for professional evaluation, and the Russian clinical studies were conducted under medical supervision in diagnosed patients, not as unsupervised self-experimentation.

Where it fits in cognitive-nootropic research

Selank is the calmer half of this desk's pair — studied for anxiolytic rather than cognitive-enhancement endpoints, but arriving at a similar practical place: people who are less anxious can think more clearly. Contrasted with Semax, it is the more defensive of the two compounds, working by quieting interference rather than amplifying output.

The evidence base has the same structural vulnerabilities: single-region Russian origin, preclinical animal work at its foundation, and thin independent human replication. What distinguishes Selank slightly is that it has at least one human dataset examining immune biomarkers in a real patient population ^[12] — something Semax's most-cited nootropic claims lack. See the comparison page for a structured side-by-side of both compounds across the key dimensions.